Last reviewed · How we verify
Jardiance
At a glance
| Generic name | Jardiance |
|---|---|
| Also known as | empagliflozin, Empagliflozin 10 mg tablets, Empagliflozin |
| Sponsor | University of Louisville |
| Target | Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Chronic heart failure
- Diabetes mellitus type 2
Common side effects
- Urinary tract infections
- Female genital mycotic infections
- Upper respiratory tract infection
- Dyslipidemia
- Increased urination
- Arthralgia
- Male genital mycotic infections
- Nausea
- Thirst/Polydipsia
Serious adverse events
- Volume depletion (blood pressure decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, syncope)
Key clinical trials
- Antithrombotic Activities of Sotagliflozin vs. Empagliflozin (PHASE4)
- Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- SGLT2i Therapy in Islet Transplantation (SIT) (PHASE4)
- Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
- A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension (PHASE1)
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart (PHASE3)
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jardiance CI brief — competitive landscape report
- Jardiance updates RSS · CI watch RSS
- University of Louisville portfolio CI